| TOP STORY | How a Silly Putty Ingredient Could Advance Stem Cell Therapies The sponginess of the environment where human embryonic stem cells are growing affects the type of specialized cells they eventually become, a new study shows. Researchers coaxed human embryonic stem cells to turn into working spinal cord cells more efficiently by growing the cells on a soft, ultrafine carpet made of a key ingredient in Silly Putty. [Press release from the University of Michigan discussing online prepublication in Nature Materials] Press Release | Abstract | |
| REVIEWS | Stem Cell Imaging: From Bench to Bedside The authors discuss how in vivo molecular imaging has helped identify barriers to clinical translation and potential strategies that may contribute to successful transplantation and improved outcomes, with a focus on cardiovascular and neurological diseases. [Cell Stem Cell] Abstract Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field. |
| SCIENCE NEWS | Baxter Meets Primary Efficacy Endpoint in Phase III Trial of BAX 111, Investigational Stand-Alone Recombinant Treatment for Von Willebrand Disease Baxter International Inc. announced topline results from a Phase III clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111. BAX 111 is a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. [Baxter International Inc.] Press Release Dicerna Pharmaceuticals Initiates Phase I Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies Dicerna Pharmaceuticals, Inc. announced the initiation of a Phase I dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC is a Dicer Substrate siRNA that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. [Dicerna Pharmaceuticals, Inc.] Press Release |
| BUSINESS | Aastrom Announces Definitive Agreement to Acquire Sanofi’s Cell Therapy and Regenerative Medicine Business Aastrom Biosciences, Inc. announced that it has entered into a definitive agreement to acquire Sanofi’s Cell Therapy and Regenerative Medicine business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. [Aastrom Biosciences, Inc.] Press Release BioCision’s Proprietary Temperature Standardization Technology to be used in TxCell Phase IIb Cell Therapy Clinical Trial in the Treatment of Crohn’s Disease BioCision, LLC announced that several of the company’s products used to support temperature control, as well as processing and handling of cell therapy products, will be used in a Phase IIb clinical trial conducted by TxCell. The trial will investigate the use of Ovasave®, an antigen-specific regulatory T autologous cell-based immunotherapy for the treatment of patients with moderate to severe refractory Crohn’s disease. [BioCision, LLC] Press Release ReNeuron Signs Agreement to Lease a New R&D, Manufacturing and Headquarters Facility in South Wales ReNeuron Group plc, the UK-based stem cell therapy company, announced that it has signed an agreement with the Welsh Government to lease a landmark building at Pencoed Technology Park, near Cardiff, South Wales. [ReNeuron Group plc] Press Release inVentiv Health Clinical Engaged by IntelliCell Biosciences, a Regenerative Medicine Company, as Clinical Research Organization for Osteoarthritis IND inVentiv Health Clinical announced that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by IntelliCell BioSciences, Inc. IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee. [inVentiv Health Clinical] Press Release First Volunteers to Receive Blood Cultured from Stem Cells in 2016 Red blood cells cultured in a laboratory will be trialed in human volunteers for the first time within the next three years, as part of a long-term research program funded by the Wellcome Trust. The £5 million Strategic Award was granted to a consortium led by the Scottish National Blood Transfusion Service, and will follow on from previous research that proved that red blood cells could be generated from stem cells. [Wellcome Trust] Press Release Neuralstem Spinal Cord Injury Stem Cell Trial Approved to Commence at University of California, San Diego Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury with its NSI-566 stem cells. [Neuralstem, Inc.] Press Release Clinical Trial Investigates Cord Blood Stem Cells to Treat Cerebral Palsy in Children Cord Blood Registry® announced the launch of an FDA-regulated clinical trial being conducted at The University of Texas Health Science Center at Houston to investigate two forms of stem cell therapy in children diagnosed with cerebral palsy. The randomized, placebo-controlled study aims to compare the safety and efficacy of an intravenous infusion of cord blood stem cells to bone marrow stem cells. [Cord Blood Registry®] Press Release AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia AAVLife, a gene-therapy company focusing on rare diseases, announced that it has raised $12 million in Series A financing to advance into clinical studies the promising work on Friedreich’s ataxia recently reported in Nature Medicine. [Business Wire] Press Release |
|